An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Kindai University. Completed at 1 site in Japan. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Kindai University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan — 13 open to participants now, 16 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Japan.
Among the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan, this one is the 20th largest by enrollment of the 20 observational ones that give a count, is one of 6 that started in 2019, is one of 20 observational ones, and was the 82nd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →13 of the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan, United States
Ages 40–80
Eli Lilly and Company · Sites in Japan, United States, Argentina and 15 more countries
Ages 40–75
Pfizer · Sites in Japan, United States, Argentina and 15 more countries
Ages 35–80
GlaxoSmithKline · Sites in Japan, United States, Argentina and 22 more countries
Ages 40–75
Sanofi · Sites in Japan, United States, Argentina and 19 more countries
Ages 40–85
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 55 · Phase 4 6
First in 2002; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 619 across the 88 interventional studies, 709 across the 20 observational. Of the 92 that completed or were terminated, 58 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 108 have an industry lead sponsor. The 10 most frequent:
Kindai University is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Kindai University has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07311499Kumamoto UniversityImprovement of Sleep in COPD Patients Through Inhalation Management Education by Nurse. | 2026-12 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07108166Philip Morris Products S.A.Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | 2027-02 |
| NCT06332885Pulmonx CorporationZephyr Valve Japan Post-Marketing Surveillance | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Dysphagia is frequently observed in subjects with chronic obstructive pulmonary disease (COPD). But tongue strength has not been investigated yet in COPD subjects. The investigators hypothesized that tongue strength is weaker in COPD subjects compared to normal subjects.
Methods:
This was a single-centre, observational, and cross-sectional study. Twenty-seven subjects with COPD and twenty-four age-matched control subjects were enrolled in this study. Isometric tongue strength was measured using a device fitted with a disposable oral balloon probe. The investigators also evaluated handgrip strength, gait speed, and appendicular skeletal muscle mass (ASM) to define participants as having sarcopenia. ASM, fat free mass index (FFMI), and skeletal muscle mass index (SMI) were measured by bioelectrical impedance analysis. Gait speed was measured using the 6-meter walking test. The eating assessment test-10 (EAT-10) was used to diagnose dysphagia.
COPD subjects were chosen from a group of subjects who had visited the Department of Respiratory Medicine and Allergology at Kindai University Hospital from December 2019 to May 2020.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: balloon-based tongue pressure measurement device
Diagnostic Test: balloon-based tongue pressure measurement device
The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
Also known as: Bioelectrical impedance analysis
maximum tongue pressure
To measure maximum tongue pressure (MTP), the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
Time frame: 1 day
handgrip strength
Handgrip strength was measured three times for the right hand using a grip strength dynamometer and mean values were used.
Time frame: 1 day
fat free mass index (FFMI)
FFMI (kg/m\^2) was calculated by fat free mass/height\^2(m\^2).
Time frame: 1 day
skeletal muscle mass (SMI)
SMI (kg/m\^2) was calculated by skeletal muscle mass /height\^2(m\^2).
Time frame: 1 day
fat free mass
Fat free mass was measured using the medical body composition analyzer. It is designed for measurements in the supine position, using four pairs of electrodes (eight electrodes in total), positioned on each hand and foot21. Supine measurements were taken after lying down for 10 minutes. Alcohol was prohibited for 24h prior to the impedance measurements.
Time frame: 1 day
skeletal muscle mass
Skeletal muscle mass was measured using the medical body composition analyzer. It is designed for measurements in the supine position, using four pairs of electrodes (eight electrodes in total), positioned on each hand and foot21. Supine measurements were taken after lying down for 10 minutes. Alcohol was prohibited for 24h prior to the impedance measurements.
Time frame: 1 day
height
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2019 to primary completion in May 2020, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Kindai University